Solid state NMR and bioequivalence comparison of the pharmacokinetic parameters of two formulations of clindamycin

International Journal of Clinical Pharmacology and Therapeutics

Volumn 49, Issue 7, 2011, Pages 469-476

  Al Talla, Z A ^a   Akrawi, S H ^b   Emwas, A H M ^a  

^a KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Saudi Arabia)

^b AL AIN UNIVERSITY   (United Arab Emirates)

Author keywords

Bioequivalence study; Clindamycin; HPLC; NMR; Pharmacokinetics

Indexed keywords

CLINDAMYCIN; CLINDOX; GENERIC DRUG; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG HALF LIFE; DRUG STRUCTURE; DRUG TOLERABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE; PATIENT COMPLIANCE; PHYSICAL EXAMINATION; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SOLID STATE;

ADULT; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; BODY WEIGHT; CALIBRATION; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CLINDAMYCIN; HUMANS; INDICATORS AND REAGENTS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; QUALITY CONTROL; REPRODUCIBILITY OF RESULTS; THERAPEUTIC EQUIVALENCY;

EID: 79960182522     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP201478     Document Type: Article

References (29)

1. Feldman S, Careccia RE, Barham KL, Hancox J. Diagnosis and treatment of acne. American Family Physician. 2004; 69: 2123-2130.
2. Metzler CM, DeHaan R, Schellenberg D, Vandenbosch WD. Clindamycin dose-bioavailability relationships. J Pharm Sci. 1973; 62: 591-598. doi:10.1002/jps.2600620410 PubMed
3. U.S. Department of Health and Human Services. Statistical Approaches to Establishing Bioequivalence. In: Food and Drug Administration; 2001. http://www.fda.gov/cder/guidance/index.htm
4. Forist AA, DeHaan RM, Metzler CM. Clindamycin bioavailability from clindamycin-2-palmitate and clindamycin-2-hexadecylcarbonate in man. J Pharmacokinet Biopharm. 1973; 1: 89-98. doi:10.1007/BF01059623 PubMed
5. Endrenyi L, Amidon GL, Midha KK, Skelly JP. Individual bioequivalence: Attractive in principle, difficult in practice. Pharmaceutical Research. 1998; 15: 1321-1325.
6. Chow S-C. Liu J-P. Design and Analysis of Bioavailability and Bioequivalence Studies: Chapman and Hall/CRC; 2008.
7. Brunton L, Lazo J, Parker K. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 11 edn: McGraw-Hill Professional; 2005. p. 1984.
8. Daum RS. Skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus 2007; 357: 380.
9. Erratum in: N Engl J Med. 2007; 357: 1357-1357.
10. Kremsner PG. Clindamycin in malaria treatment. J Antimicrob Chemother. 1990; 25: 9-14. doi:10.1093/jac/25.1.9 PubMed
11. Lell B, Kremsner PG. Clindamycin as an antimalarial drug: review of clinical trials. Antimicrob Agents Chemother. 2002; 46: 2315-2320. doi:10.1128/AAC.46.8.2315-2320.2002 PubMed
12. Gibaldi M. Perrier D. Pharmacokinetics. 2 edn: Informa Healthcare; 1982. p. 504.
13. Brown LW. GLC determination of clindamycin and related compounds. J Pharm Sci. 1974; 63: 1597-1600. doi:10.1002/jps.2600631022 PubMed
14. Townsend RJ, Baker RP. Pharmacokinetic Comparison of Clindamycin Dosing - Reply. Drug Intell Clin Pharm. 1987; 21: 662.
15. Aso Y, Yoshioka S. Molecular mobility of nifedipine-PVP and phenobarbital-PVP solid dispersions as measured by 13C-NMR spin-lattice relaxation time. J Pharm Sci. 2006; 95: 318-325. doi:10.1002/jps.20545 PubMed
16. Wawer I, Diehl B. Holzgrabe U. NMR Spectroscopy in Pharmaceutical Analysis. 1 edn: Elsevier Science; 2008. p. 528.
17. Kalachandra S, Lin DM, Stejskal EO, Prakki A, Offenbacher S. Drug release from cast films of ethylene vinyl acetate (EVA) copolymer: Stability of drugs by 1H NMR and solid state 13C CP/MAS NMR. J Mater Sci Mater Med. 2005; 16: 597-605. doi:10.1007/s10856-005-2529-1 PubMed
18. Novoselsky A, Glaser R. Solid state CP/MAS 13C NMR studies on conformational polymorphism in sertraline hydrochloride, an antidepressant drug. Magn Reson Chem. 2002; 40: 723-728. doi:10.1002/mrc.1093
19. Terskikh W, Lang SJ, Gordon PG, Enright GD, Ripmeester JA. (13)C CP MAS NMR of halogenated (Cl, Br, I) pharmaceuticals at ultrahigh magnetic fields. Magn Reson Chem. 2009; 47: 398-406. doi:10.1002/mrc.2399 PubMed
20. U.S. Department of Health and Human Services. Bioavailability and Bioequivalence Studies for Orally Administered Drug Products - General Considerations. In: Food and Drug Administration; 2003.http://www.fda.gov/cder/ guidance/index.htm
21. Shah VP, Midha KK, Dighe S, McGilveray IJ, Shelly JP, Yacobi A, Layloff T, Viswanathan CT, Cook CE, McDowell RD, Pittman KA, Spector S. Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. Conference report. Pharm Res. 1992; 9: 588-592.
22. Dadgar D, Burnett PE, Choc MG, Gallicano K, Hooper JW. Application issues in bioanalytical method validation, sample analysis and data reporting. J Pharm Biomed Anal. 1995; 13: 89-97. doi:10.1016/0731-7085(94)00106-C PubMed
23. Liu CM, Chen YK, Yang TH, Hsieh SY, Hung MH, Lin ET. High-performance liquid chromatographic determination of clindamycin in human plasma or serum: application to the bioequivalency study of clindamycin phosphate injections. J Chromatogr B Biomed Sci Appl. 1997; 696: 298-302. doi:10.1016/S0378-4347(97) 00241-7 PubMed
24. La Follette G, Gambertoglio J, White JA, Knuth DW, Lin ET. Determination of clindamycin in plasma or serum by high-performance liquid chromatography with ultraviolet detection. J Chromatogr A. 1988; 431: 379-388. PubMed
25. Watson D. Pharmaceutical Analysis: A Textbook for Pharmacy Students and Pharmaceutical Chemists: Churchill Livingstone; 2005.
26. Walker R. Whittlesea C. Clinical Pharmacy and Therapeutics: Churchill Livingstone; 2007.
27. The European Agency for the Evaluation of Medicinal Products. The investigation of bioavailability and bioequivalence. In: Department of Health and Ageing. London, UK; 26, July 2001. http://www.eudra.org/emea.html
28. U.S. Department of Health and Human Services. Bioanalytical Method Validation. In: Food and Drug Administration; 2001. http://www.fda.gov/cder/ guidance/index.htm
29. Tso, Office UKBPCtS, Staff T. British Pharmacopoeia: Bernan Press(PA); 2000.